GE Fabienne Warmerdam Zuyderland
Disclosure ASCO 2017 travelgrant Pfizer
CRC ADJUVANT Less is more? More is More!
1 Less is more?
Perspectief INT-0035 stadium III (niets vs 5-FU) 6.5-jaars OS 46% vs. 60% MOSAIC stadium III (5-FU/LV vs + oxaliplatin) 10-jaars OS 59.0% vs. 67.1%
The BIG Problem: Large Proportion of Patients with Residual Neuropathy at 4 yrs Presented By Cathy Eng at 2017 ASCO Annual Meeting
Prospective Pooled Analysis of Six Phase III Trials Investigating Duration of Adjuvant Oxaliplatin-based therapy (3 vs. 6 months) for Patients with Stage III Colon Cancer: <br />The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration Presented By Qian Shi at 2017 ASCO Annual Meeting
Study Schema Presented By Qian Shi at 2017 ASCO Annual Meeting
Rationale for Non-inferiority Margin Presented By Qian Shi at 2017 ASCO Annual Meeting
DFS Comparison by Stage, cont. Presented By Qian Shi at 2017 ASCO Annual Meeting
DFS Comparison by Regimen, cont. Presented By Qian Shi at 2017 ASCO Annual Meeting
DFS Comparison by Risk Group and Regimen, cont. Presented By Qian Shi at 2017 ASCO Annual Meeting
Adverse Events Presented By Qian Shi at 2017 ASCO Annual Meeting
<br /><br /><br /> Presented By Timothy Iveson at 2017 ASCO Annual Meeting
IDEA Clinical Consensus: Risk-based approach to adjuvant chemotherapy in stage III colon cancer Presented By Qian Shi at 2017 ASCO Annual Meeting
Discussie Cathy Eng
Findings: Presented By Cathy Eng at 2017 ASCO Annual Meeting
Findings: Presented By Cathy Eng at 2017 ASCO Annual Meeting
Potential Pitfalls of the Pooled Data: Presented By Cathy Eng at 2017 ASCO Annual Meeting
Comments. Presented By Cathy Eng at 2017 ASCO Annual Meeting
Conclusions: Presented By Cathy Eng at 2017 ASCO Annual Meeting
Voor nu Geen verandering richtlijn Bij T3N1met CAPOX dosisreductie/stop oxaliplatin na 4 cycli bij PNP
2 Nuts for Guts or Guts for Nuts
Nut Consumption and Survival in Stage III Colon Cancer Patients: Results from CALGB 89803 (Alliance)
CALGB 89803
CALGB 89803
Results
Results
Secondary analyses of 89803
More is more
Voor nu Leefstijl adviezen in richtlijn Post-treatment program (zoals Herstel & Balans) inclusief dieet- en leefstijl adviezen
CRC gemetastaseerd Prognostische en predictieve markers
1 RECHTS vs LINKS
<br />Primary tumor location is an independent prognostic marker from molecular features for overall survival in patients with metastatic colorectal cancer: analysis of CALGB/SWOG 80405 (Alliance) <br /> Presented By Heinz-Josef Lenz at 2017 ASCO Annual Meeting
CALGB/SWOG 80405 Presented By Heinz-Josef Lenz at 2017 ASCO Annual Meeting
<br /> 80405: (KRAS WT) Overall Survival by Sidedness Presented By Heinz-Josef Lenz at 2017 ASCO Annual Meeting
Factors included in multivariate analysis Presented By Heinz-Josef Lenz at 2017 ASCO Annual Meeting
2 Consensus molecular subtyping (CMS)
Impact of Consensus Molecular Subtyping (CMS) on overall survival (OS) and Progression Free Survival (PFS) in patients (pts) with metastatic colorectal cancer (mcrc): Analysis of CALGB / SWOG 80405 (Alliance). Presented By Heinz-Josef Lenz at 2017 ASCO Annual Meeting
Slide 3 Presented By Robert Coffey at 2017 ASCO Annual Meeting
CMS Subgroups Presented By Sebastian Stintzing at 2017 ASCO Annual Meeting
Relation of Genotype to Phenotype<br />Colorectal Molecular Subtypes Presented By Alan Venook at 2017 ASCO Annual Meeting
Slide 32 Presented By Heinz-Josef Lenz at 2017 ASCO Annual Meeting
Slide 33 Presented By Heinz-Josef Lenz at 2017 ASCO Annual Meeting
Slide 34 Presented By Heinz-Josef Lenz at 2017 ASCO Annual Meeting
Slide 35 Presented By Heinz-Josef Lenz at 2017 ASCO Annual Meeting
Conclusion Presented By Heinz-Josef Lenz at 2017 ASCO Annual Meeting
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and 1st-line efficacy of FOLFIRI plus cetuximab or bevacizumab Presented By Heinz-Josef Lenz at 2017 ASCO Annual Meeting
FIRE-3 Design Presented By Heinz-Josef Lenz at 2017 ASCO Annual Meeting
OS in RAS wild-type Presented By Heinz-Josef Lenz at 2017 ASCO Annual Meeting
CMS4: FOLFIRI cetuximab vs. FOLFIRI bevacizumab Presented By Heinz-Josef Lenz at 2017 ASCO Annual Meeting
FOLFIRI cetuximab vs. FOLFIRI bevacizumab Presented By Heinz-Josef Lenz at 2017 ASCO Annual Meeting
Voor nu Geen veranderingen behandeling mcrc
Immunotherapie in CRC 10-15% MSI 19 ptn >= 2 lijnen Na 3 maanden: DCR 68% CR 5% PR 47% SD 16%
Cholangiocarcinoom adjuvant Nieuw!
Slide 4 Presented By John Primrose at 2017 ASCO Annual Meeting
Slide 6 Presented By Tanios Bekaii-Saab at 2017 ASCO Annual Meeting
Outcomes Measures according to ITT and PP analyses*,^ Presented By Tanios Bekaii-Saab at 2017 ASCO Annual Meeting
Summary slide : Adjuvant Therapy in Biliary Cancer (BTC) Presented By Tanios Bekaii-Saab at 2017 ASCO Annual Meeting
Voor nu 6 maanden adjuvant capecitabine wordt standaard voor cholangiocarcinoom
Oesophagus-maag perioperatief taxanen
Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4): A multicenter, randomized phase 3 trial Presented By Salah-Eddin Al-Batran at 2017 ASCO Annual Meeting
Perspectief MAGIC Trial niets vs ECC 23% vs 36%
FLOT4 Study Design Presented By Salah-Eddin Al-Batran at 2017 ASCO Annual Meeting
Histopathology (yptn) Presented By Salah-Eddin Al-Batran at 2017 ASCO Annual Meeting
Operative Morbidity/Mortality Presented By Salah-Eddin Al-Batran at 2017 ASCO Annual Meeting
Chemo Related Toxicity 1 Presented By Salah-Eddin Al-Batran at 2017 ASCO Annual Meeting
Chemo Related Toxicity 2 Presented By Salah-Eddin Al-Batran at 2017 ASCO Annual Meeting
FLOT4: Progression-Free Survival Presented By Salah-Eddin Al-Batran at 2017 ASCO Annual Meeting
FLOT4: Overall Survival Presented By Salah-Eddin Al-Batran at 2017 ASCO Annual Meeting
Voor nu FLOT wordt nieuwe standaard peri-operatieve therapie maagcarcinoom
Oesophagus-maag gemetastaseerd Immunotherapie
Anti-PD1
ATTRACTION 2: Phase III of NIVOLUMAB vs. Placebo in G/GEC Presented By Tanios Bekaii-Saab at 2017 ASCO Annual Meeting
KEYNOTE-059 Cohort 1: Efficacy and Safety of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric Cancer Presented By Charles Fuchs at 2017 ASCO Annual Meeting
KEYNOTE-059 (NCT02335411): Phase 2 Multicohort Study of Pembrolizumab for G/GEJ Adenocarcinoma<br /> Presented By Charles Fuchs at 2017 ASCO Annual Meeting
KEYNOTE-059 Cohort 1 Eligibility Criteria Presented By Charles Fuchs at 2017 ASCO Annual Meeting
Response in All Patients Presented By Charles Fuchs at 2017 ASCO Annual Meeting
Maximum Percentage Change From Baseline in<br />Target Lesion Sizea Presented By Charles Fuchs at 2017 ASCO Annual Meeting
Treatment Exposurea and Duration of Response Presented By Charles Fuchs at 2017 ASCO Annual Meeting
OS in All Patients Presented By Charles Fuchs at 2017 ASCO Annual Meeting
Response by MSI Status (n = 174) Presented By Charles Fuchs at 2017 ASCO Annual Meeting
Conclusions Presented By Charles Fuchs at 2017 ASCO Annual Meeting
Conclusions Presented By Charles Fuchs at 2017 ASCO Annual Meeting
Anti-PD1 + anti-ctla-4
Nivolumab ± Ipilimumab in Patients With Advanced/Metastatic Chemotherapy-Refractory Gastric, Esophageal, or Gastroesophageal Junction Cancer: CheckMate 032 Study Presented By Yelena Janjigian at 2017 ASCO Annual Meeting
Nivolumab ± ipilimumab in patients with advanced/metastatic chemotherapy-refractory gastric, esophageal, or gastroesophageal junction cancer: CheckMate 032 study Presented By Tanios Bekaii-Saab at 2017 ASCO Annual Meeting
Overall Survival Presented By Tanios Bekaii-Saab at 2017 ASCO Annual Meeting
Summary slide : Immunotherapy in Advanced Gastro-Esophageal Cancer Presented By Tanios Bekaii-Saab at 2017 ASCO Annual Meeting
Voor nu Immunotherapie oesophagus/maag nog geen optie in gemetastaseerde setting (PASKWIL criteria?) Onderzoek in adjuvante setting volgt
Ergo: Practice-changing in GI CRC adjuvant 6 mnd CAPOX, T3N1 eventueel stop na 3 mnd bij tox Leefstijl- en voedingsadviezen! Cholangiocarcinoom adjuvant capecitabine Maagcarcinoom perioperatief FLOT
PASKWIL criteria 2016